Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC(50)?

類似資料

• Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
  著者:: Martinelli, Giovanni, 等
  出版事項: (2007)
• Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
  著者:: Soverini, Simona, 等
  出版事項: (2016)
• Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
  著者:: Martinelli, Giovanni, 等
  出版事項: (2009)
• Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
  著者:: Soverini, Simona, 等
  出版事項: (2011)
• Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
  著者:: Mesa, Ruben A
  出版事項: (2007)